These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 24934847

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
    Herishanu Y, Tadmor T, Braester A, Bairey O, Aviv A, Rahimi-Levene N, Fineman R, Levi I, Yuklea M, Ruchlemer R, Shvidel L, Polliack A.
    Hematol Oncol; 2019 Apr; 37(2):185-192. PubMed ID: 30756414
    [Abstract] [Full Text] [Related]

  • 3. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
    Howard DR, Munir T, McParland L, Rawstron AC, Chalmers A, Gregory WM, O'Dwyer JL, Smith A, Longo R, Varghese A, Smith A, Hillmen P.
    Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Foon KA, Boyiadzis M, Land SR, Marks S, Raptis A, Pietragallo L, Meisner D, Laman A, Sulecki M, Butchko A, Schaefer P, Lenzer D, Tarhini A.
    J Clin Oncol; 2009 Feb 01; 27(4):498-503. PubMed ID: 19075274
    [Abstract] [Full Text] [Related]

  • 7. [Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].
    Fang C, Xu W, Xu M, Hong M, Zhu DX, Zhu HY, Wu YJ, Fan L, Qiao C, Zhuang Y, Miao KR, Liu P, Li JY.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan 01; 32(1):3-7. PubMed ID: 21429392
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.
    Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC, LUCID trial investigators.
    Br J Haematol; 2014 Nov 01; 167(4):466-77. PubMed ID: 25130401
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
    Herishanu Y, Goldschmidt N, Bairey O, Ruchlemer R, Fineman R, Rahimi-Levene N, Shvidel L, Tadmor T, Ariel A, Braester A, Shapiro M, Joffe E, Polliack A, Israeli CLL Study Group.
    Haematologica; 2015 May 01; 100(5):662-9. PubMed ID: 25661442
    [Abstract] [Full Text] [Related]

  • 12. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
    Hillmen P, Cohen DR, Cocks K, Pettitt A, Sayala HA, Rawstron AC, Kennedy DB, Fegan C, Milligan DW, Radford J, Mercieca J, Dearden C, Ezekwisili R, Smith AF, Brown J, Booth GA, Varghese AM, Pocock C, NCRI CLL Sub-Group.
    Br J Haematol; 2011 Mar 01; 152(5):570-8. PubMed ID: 21231927
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome.
    Laurenti L, De Padua L, Tarnani M, Piccirillo N, Falcucci P, D'Arena G, Innocenti I, Marietti S, Efremov DG, Chiusolo P, Zini G, Sora' F, Sica S, Leone G.
    Ann Hematol; 2011 Jan 01; 90(1):59-65. PubMed ID: 20625902
    [Abstract] [Full Text] [Related]

  • 16. Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group.
    Smolej L, Brychtová Y, Cmunt E, Doubek M, Špaček M, Belada D, Šimkovič M, Stejskal L, Zygulová I, Urbanová R, Brejcha M, Zuchnická J, Móciková H, Kozák T, Czech CLL Study Group.
    Br J Haematol; 2021 May 01; 193(4):769-778. PubMed ID: 33618437
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia.
    Forconi F, Fabbri A, Lenoci M, Sozzi E, Gozzetti A, Tassi M, Raspadori D, Lauria F.
    Hematol Oncol; 2008 Dec 01; 26(4):247-51. PubMed ID: 18642397
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
    Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, Crombie J, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Fisher DC, Brown JR, Blood Cancer Research Partnership of the Leukemia & Lymphoma Society.
    Lancet Haematol; 2019 Aug 01; 6(8):e419-e428. PubMed ID: 31208944
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.